Rationale for Semaglutide in MASH: Impact on Metabolism and Liver Fat Data from the ongoing phase 3, multicentre, placebocontrolled ESSENCE trial involving patients with biopsyconfirmed MASH and liver fibrosis (stage F2 or F3) demonstrated that subcutaneous semaglutide 2.4 mg/week not only improves steatosis but also reduces necroinflammation, hepatocellular ballooning and fibrosis [8]
This post is intended for informational purposes only and is not a substitute for professional medical advice
For most people, this is impractical and increases the risk of dosing errors
GLP-1 medications are available through the program but are billed separately from the monthly membership fee
It is gradually increased over several weeks to the target dose
Clean the site, pinch a fold of skin, insert the needle at 90 degrees (your prescriber may suggest 45 degrees if you are very lean), press the plunger slowly all the way down, count to five, then withdraw